Trial Profile
A Randomized, Open-label, Comparative, Non-inferiority, Multicenter Study to Compare Efficacy of Losartan Potassium Group and Carvedilol Group on Arterial Stiffness in Essential Hypertension Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Losartan (Primary) ; Losartan/hydrochlorothiazide (Primary) ; Carvedilol; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms LAAS
- Sponsors Organon
- 10 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.